Highlights
- Market Cap
- $263.58K
- Enterprise Value
- -$1.55B
- EPS (TTM)
- -$284.19
- Total Revenue (TTM)
- $173.67K
- Gross Profit (TTM)
- -$2.67M
- EBITDA (TTM)
- -$1.26B
- Year Range
- $0.05 - $0.63
- ROA (TTM)
- -53.54%
- ROE (TTM)
- -84.58%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Lipella Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Lipella Pharmaceuticals Inc.
- 1D
- -17.35%
- 1M
- -63.79%
- YTD
- -67.81%
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Oct 17, 2025, LIPO's average daily return is -1.35%, while the average monthly return is -24.74%.
Historically, 17% of months were positive and 83% were negative. The best month was Jan 2026 with a return of +60.2%, while the worst month was Mar 2026 at -63.8%. The longest winning streak lasted 1 consecutive months, and the longest losing streak was 3 months.
On a daily basis, LIPO closed higher 28% of trading days. The best single day was Jan 30, 2026 with a return of +68.6%, while the worst single day was Mar 27, 2026 at -49.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 60.17% | -44.50% | -63.79% | -67.81% | |||||||||
| 2025 | -30.73% | -24.14% | -45.45% | -71.34% |
Benchmark Metrics
Lipella Pharmaceuticals Inc. has an annualized alpha of -96.66%, beta of 0.84, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since October 20, 2025.
- This stock participated in 458.45% of S&P 500 Index downside but only -279.83% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -96.66%
- Beta
- 0.84
- R²
- 0.00
- Upside Capture
- -279.83%
- Downside Capture
- 458.45%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Lipella Pharmaceuticals Inc. (LIPO) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lipella Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lipella Pharmaceuticals Inc. was 90.77%, occurring on Mar 31, 2026. The portfolio has not yet recovered.
The current Lipella Pharmaceuticals Inc. drawdown is 90.77%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -90.77% | Oct 20, 2025 | 112 | Mar 31, 2026 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lipella Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Lipella Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LIPO relative to other companies in the Biotechnology industry. Currently, LIPO has a P/S ratio of 1.5. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LIPO in comparison with other companies in the Biotechnology industry. Currently, LIPO has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |